<DOC>
	<DOCNO>NCT00366834</DOCNO>
	<brief_summary>This Phase III trial design demonstrate casopitant ( GW679769 ) plus dexamethasone ondansetron effective prevention vomit dexamethasone ondansetron alone follow administration moderately emetogenic chemotherapy .</brief_summary>
	<brief_title>Intravenous And Oral Casopitant ( GW679769 ) For The Prevention Of Chemotherapy Induced Nausea And Vomiting</brief_title>
	<detailed_description>A Phase III , Multicenter , Randomized , Double-Blind , Active Controlled , Parallel Group Study Safety Efficacy Intravenous Oral Formulations Neurokinin-1 Receptor Antagonist , Casopitant ( GW679769 ) Combination Ondansetron Dexamethasone Prevention Nausea Vomiting Induced Moderately Emetogenic Chemotherapy</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Inclusion criterion : A subject consider eligible inclusion study follow criterion apply : Subject understand nature purpose study study procedure sign informed consent form study indicate understanding . At least 18 year age . Is schedule receive first course anthracycline cyclophosphamide contain moderately emetogenic chemotherapy regimen treatment solid malignant tumor outline Section 8.1.1 . Has ECOG performance status 0 , 1 , 2 . Hematologic metabolic status must adequate receive moderately emetogenic regimen meet follow criterion : Total Neutrophils ≥ 1500/mm³ ( Standard unit : ≥1.5 x 10^9/L ) Platelets ≥ 100,000/mm³ ( Standard unit : ≥100.0 x 10^9/L ) Bilirubin ≤ 1.5 x ULN Liver enzymes must follow limit : Without know liver metastasis : Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) ≤ 2.5 x upper limit normal . With know liver metastasis : AST and/or ALT ≤ 5.0 x upper limit normal . Is willing able complete daily component subject diary study cycle . Women childbearing potential ; must commit consistent correct use acceptable method birth control ; GSK acceptable contraceptive method , use consistently accordance product label instruction physician , follow : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal . For purpose study , postmenopausal define one year without menses ) 2. childbearing potential : must negative serum pregnancy test result negative urine dipstick pregnancy test within 24 hour prior first dose investigational product Cycle 1 , Day 1 agree one following : male partner sterile prior female subject 's entry study sole sexual partner female subject oral contraceptive ( e.g. , oral , injectable , implantable ) doublebarrier method contraception consist spermicide either condom diaphragm period trial account potential drug interaction ( minimum six week ) doublebarrier method contraception consist spermicide either condom diaphragm intrauterine device ( IUD ) document failure rate le 1 % per year complete abstinence intercourse two week exposure investigational product throughout clinical trial , period trial account elimination drug ( minimum three day ) , subject indicate remain abstinent period describe , must agree follow GSK guideline consistent correct use acceptable method birth control become sexually active . Exclusion criterion : Has previously receive cytotoxic chemotherapy . A history previous biological hormonal therapy permit . Is female subject pregnant lactating . Has receive radiation therapy brain , abdomen , pelvis ten day prior first dose study medication casopitant investigational product and/or receive radiation therapy brain , abdomen , pelvis six day follow first dose study medication ( ZOFRAN dexamethasone ) casopitant investigational product . Is schedule receive taxane therapy cycle 1 . Note subject permit receive taxane therapy conjunction one allow MEC regimens subsequent cycle . Has experience emesis ( i.e. , vomit and/or retch ) clinically significant nausea 24 hour precede first dose study medication casopitant investigational product . Has know central nervous system primary metastatic malignancy , unless successfully treat excision radiation medically stable least 1 week prior receive first dose study medication casopitant investigational product . Has history document peptic ulcer disease ( via endoscopy xray ) , active peptic ulcer disease , gastrointestinal obstruction , increase intracranial pressure , hypercalcemia , uncontrolled medical condition ( malignancy ) opinion Investigator may confound result study , represent another potential etiology emesis nausea ( CINV ) pose unwarranted risk subject . Has know hypersensitivity contraindication ZOFRAN , another 5HT3 receptor antagonist , dexamethasone , component casopitant . Has previously receive NK1 receptor antagonist . Received investigational drug previous 30 day schedule receive investigational drug casopitant study period . Has taken/received medication moderate high emetogenic potential within 48 hour prior first dose study medication casopitant investigational product . Opioid narcotic cancer pain permit subject stable dose experience emesis nausea narcotic . Has taken/received medication know potential antiemetic activity within 24hour period prior receive study drug . This include , limit : 5HT3 receptor antagonist ( e.g. , ondansetron , granisetron , dolasetron , tropisetron , ramosetron ) . Palonestron permit within 7 day prior administration investigational product . benzamide / benzamide derivative ( e.g. , metoclopramide , alizapride ) benzodiazepine ( except subject receive medication sleep anxiety stable dose least seven day prior first dose casopitant investigational product ; however , lorazepam prohibit 24 hour prior receive study drug regardless reason use ) phenothiazine ( e.g. , prochlorperazine , promethazine , fluphenazine , perphenazine , thiethylperazine , chlorpromazine ) butyrophenone ( e.g. , haloperidol , droperidol ) corticosteroid ( e.g. , dexamethasone , methylprednisolone ; exception topical steroid skin disorder , inhaled steroid respiratory disorder , prophylactic treatment taxane therapy subsequent cycle ) anticholinergic ( e.g. , scopolamine , exception inhale anticholingerics respiratory disorder e.g. , ipratropium bromide ) antihistamine ( e.g. , cyclizine , hydroxyzine , diphenhydramine ) , except prophylactic use taxane therapy cycle 24 domperidone cannabinoids mirtazpine olanzapine Has taken/received strong moderate inhibitor CYP3A4 CYP3A5 specify period prior administration casopitant investigational product ( see Section 8.2.1 `` Inhibitors CYP3A4 CYP3A5 '' ) Has taken/received inducer CYP3A4 CYP3A5 within fourteen day prior administration casopitant investigational product . ( see Section 8.2.2 `` Inducers CYP3A4 CYP3A5 '' ) Is take antidiabetic agent repaglinide diuretic torsemide . Investigators advise exercise caution include patient take antidiabetic agent rosiglitazone pioglitazone , antimalarial agent chloroquine amodiaquine , metabolite casopitant potential inhibitor CYP2C8 ( See Section 8.2.3 `` Substrates CYP2C8 '' Section 8.4 `` Necessary Caution CYP2C8 Substrates '' ) . Is currently take plan take follow CYP3A4 substrate : astemizole , cisapride , pimozide , terfenadine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Anthracycline</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Moderately</keyword>
	<keyword>Nausea</keyword>
	<keyword>Emetogenic</keyword>
	<keyword>Vomiting</keyword>
</DOC>